JAMA Network
About The Study: In people with inadequately controlled type 2 diabetes treated with basal insulin in this randomized clinical trial with 1,428 participants, weekly tirzepatide compared with prandial insulin as an additional treatment with insulin glargine demonstrated reductions in HbA1c and body weight with less hypoglycemia.
Authors: Julio Rosenstock, M.D., of Velocity Clinical Research at Medical City in Dallas, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.20294)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
